CWM
CNTX icon

Congress Wealth Management’s Context Therapeutics CNTX Stock Holding History

Congress Wealth Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$9.83K Hold
15,000
– – ﹤0.01% 1179
2025
Q1 		$9.18K Buy
+15,000
New +$13.1K ﹤0.01% 1064

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Congress Wealth Management's CNTX Position: Q2 2025 in Review

Congress Wealth Management held its Context Therapeutics (CNTX) position steady in Q2 2025 at 15,000 shares worth $9.83K. The position accounts for ﹤0.01% of the portfolio, ranked #1179.

Congress Wealth Management first reported a position in CNTX in Q1 2025 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold CNTX as of Q2 2025.

  • Congress Wealth Management held 15,000 shares of Context Therapeutics worth $9.83K as of Q2 2025.
  • Congress Wealth Management left its Context Therapeutics share count unchanged in Q2 2025.
  • Context Therapeutics made up ﹤0.01% of Congress Wealth Management's portfolio in Q2 2025, its #1179 holding.
  • Congress Wealth Management first reported a position in Context Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2025.

Based on Congress Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.